Long-term survival in HER2-positive metastatic breast cancer treated with first-line trastuzumab: results from the french real-life curie database
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
Link
http://link.springer.com/content/pdf/10.1007/s10549-019-05423-5.pdf
Reference26 articles.
1. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(9472):1687–1717
2. Gobbini E, Ezzalfani M, Dieras V, Delaloge S et al (2018) Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort. Eur J Cancer 96:17–24
3. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344(11):783–792
4. Marty M, Cognetti F et al (2005) Superior long-term survival benefits of trastuzumab (Herceptin®) plus docetaxel compared with docetaxel alone in patients with HER2-positive metastatic breast cancer: patients surviving 4 years in the M77001 study. JCO 23:4265–4274
5. Extra J-M, Antoine EC, Vincent-Salomon A, Delozier T, Kerbrat P, Bethune-Volters A et al (2010) Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine study. Oncologist 15(8):799–809
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. The Impact of Initial Tumor Response on Survival Outcomes of Patients With HER2-Positive Advanced Breast Cancer Treated With Docetaxel, Trastuzumab, and Pertuzumab: An Exploratory Analysis of the CLEOPATRA Trial;Clinical Breast Cancer;2024-07
2. Prediction of pathological complete response to neoadjuvant chemotherapy in patients with breast cancer using a combination of contrast‐enhanced ultrasound and dynamic contrast‐enhanced magnetic resonance imaging;Cancer Medicine;2022-07-13
3. Inmunohistoquímica con anticuerpos monoclonales en mujeres indígenas peruanas con cáncer de mama, para pronosticar sobrevida global;Revista Colombiana de Cancerología;2021-12-23
4. Survival Outcomes Among Patients with Metastatic Breast Cancer: Review of 47,000 Patients;Annals of Surgical Oncology;2021-05-28
5. 18F-FHBG PET-CT Reporter Gene Imaging of Adoptive CIK Cell Transfer Immunotherapy for Breast Cancer in a Mouse Model;OncoTargets and Therapy;2020-11
18F-FHBG PET-CT Reporter Gene Imaging of Adoptive CIK Cell Transfer Immunotherapy for Breast Cancer in a Mouse Model
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3